AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04187092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KneeBright Group
Description: The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions.
Study NCT04187092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation group
Description: Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
Study NCT01071187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
Study NCT01585259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT04441463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for tryptase analysis
Description: 3 bloods test~* One blood sample taking from the mother's vein punction, during the delivery.~* One blood sample tanking from umbilical cord.~* One blood sample taking from the baby in day 3 of life, during the Guthrie test.
Study NCT01071187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00619502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, intramuscular (IM)
Study NCT00619502 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, intramuscular (IM)
Study NCT05280262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CogState Test
Description: Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
Study NCT00373217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Description: Given intradermally or subcutaneously
Study NCT02688517 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood samples
Study NCT02688517 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00373217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given intradermally or subcutaneously
Study NCT01643031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued clopidogrel
Description: Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
Study NCT00412477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV LFn-p24
Description: HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
Study NCT02617485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
Study NCT04911374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gentle Cleansing Lotion, Revision Skincare
Description: Gentle cleansing lotion to be used by study participants
Study NCT04911374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aveeno Face Milk SPF 40+
Description: Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
Study NCT00345644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: risedronate sodium 35 mg tablets (once a week dose)
Study NCT00345644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risedronate placebo
Description: placebo for risedronate tablets (once a week dose)
Study NCT03886844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Human milk fortifier based on human milk (Prolacta)
Description: Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
Study NCT03054363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib in Combination with Palbociclib and Letrozole
Description: Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily
Study NCT03054363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib in Combination with Palbociclib and Letrozole
Description: Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
Study NCT00522067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine
Description: Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
Study NCT01151683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium
Description: Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
Study NCT01151683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two capsules of placebo per oral twice a day
Study NCT00826813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal stent placement
Description: The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
Study NCT00404521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM02734
Description: Administered every 3 weeks, intravenously, over 30 minutes
Study NCT03968419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
Study NCT03968419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
Study NCT03446495 — intervention group
Intervention type: DRUG
Intervention: Trabectedin + PLD
Description: Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
Study NCT02964637 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Study NCT00373217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT04268888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and TACE/TAE
Description: Immunotherapy and TACE/TAE
Study NCT04268888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE/TAE
Description: TACE/TAE (as per local practice)
Study NCT04268888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE/TAE
Description: TACE/TAE (as per local practice)
Study NCT01533727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CIK Transfusion plus Chemotherapy
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
Study NCT01533727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy alone
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
Study NCT02395549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.375% (w/w) MTC896 Gel
Description: 0.375% (w/w) MTC896 Gel
Study NCT02395549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% (w/w) MTC896 Gel
Description: 0.75% (w/w) MTC896 Gel
Study NCT00373217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00373217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo primary optimal cytoreductive surgery
Study NCT03942120 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
Study NCT02046746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement (ONS)
Description: renal specific commercially available ONS
Study NCT01790347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week.
Study NCT03522675 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeoMatriX Wound MatriX Collagen Dressing
Description: Collagen wound dressing
Study NCT01882647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 000-0551 Lotion
Study NCT01882647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Study NCT01944800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
Study NCT01944800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/> 75 years or \< 60 kg
Study NCT03274830 — intervention group
Intervention type: DEVICE
Intervention: aneXys
Description: 150 patients with the aneXys cup
Study NCT01306630 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tivozanib (AV-951) and capecitabine (Xeloda®)
Description: Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
Study NCT01054586 — intervention group
Intervention type: DRUG
Intervention: Intervention A Standard dose
Description: HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
Study NCT02395549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% (w/w) MTC896 Gel
Description: 1.5% (w/w) MTC896 Gel
Study NCT02395549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control Gel
Study NCT01054586 — intervention group
Intervention type: DRUG
Intervention: Intervention B Reduced Dose
Description: HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
Study NCT01054586 — intervention group
Intervention type: DRUG
Intervention: Intervention C
Description: HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
Study NCT01054586 — intervention group
Intervention type: DRUG
Intervention: Intervention D
Description: HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
Study NCT01054586 — intervention group
Intervention type: DRUG
Intervention: Intervention E
Description: HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
Study NCT00594477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study NCT02280850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanxin Shutong Capsule
Description: 3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02280850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 3 capsules three times a day; Duration: 4 weeks.
Study NCT02280850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerine
Description: Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.
Study NCT02280850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitroglycerine
Description: Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.
Study NCT02327299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FePP
Study NCT02327299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FePP + Stabilizer
Study NCT02327299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FeSO4
Study NCT02327299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FeSO4 + Stabilizer
Study NCT01929057 — intervention group
Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: 4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
Study NCT01929057 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Approximately half a tube of blood will be drawn from all participants in the study
Study NCT01125332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indirect laryngoscopy in the flexible nasofibroscope
Study NCT01125332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indirect laryngoscopy in the flexible nasofibroscope
Study NCT02613208 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be administered as per local clinical practice and local labeling.
Study NCT02613208 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per local clinical practice and local labeling.
Study NCT02224235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
Study NCT02224235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity DES
Description: Resolute Integrity DES
Study NCT02224235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF
Study NCT02224235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: At the discretion of the investigator as to which DAPT is administered (per local practice)
Study NCT02224235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: At the discretion of the investigator as to which DAPT is administered (per local practice)
Study NCT03656965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 800 MG
Description: Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
Study NCT03656965 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Description: Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
Study NCT03656965 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Radiotherapy and chemotherapy
Description: Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
Study NCT00237679 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
Study NCT00237679 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Unstimulated
Description: No current is generated.
Study NCT00770445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and insulin
Description: Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
Study NCT00770445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and metformin and insulin
Description: Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
Study NCT00770445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and insulin
Description: Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.